DSOs Are Rolling Up DSOs. The Economics Are Ugly.

Park Dental Partners spent the last decade buying 43 dental practices, and in 2025 that entire acquisition machine moved the top line by roughly $1.4 million. On the company's FY2025 Form 10-K, total revenue went from $229.8 million to $244.5 million, a 6.4% increase, while same-practice revenue grew 5.8%. Subtract one from the other and the dealmaking, the diligence, the integration, the whole apparatus of a roll-up, contributed about six tenths of a percentage point.

That number matters to you for one reason. If a DSO is offering you a deal with a rollover equity component, the paper you are being handed is a claim on precisely that kind of growth, bought with debt, and it will be sold to another private equity firm before it ever pays you. Our view, and your broker will tell you we are wrong: value the rollover at zero when you compare offers, and take the deal with the most cash at close even if the headline multiple is a full turn lower. The second bite is the same apple, cut smaller, served five years later, by people who never met you.

A 43-Practice Machine That Grew Like a Single Office

Start with what the Park filing actually shows, because it is one of the few places a practice owner can see roll-up economics without an NDA. Dentist count went from 145 to 214 and locations from 63 to 86 between 2015 and 2025. Same-practice revenue growth was 1.6% in 2024 and 5.8% in 2025.

Read 2024 again. A platform with dozens of locations and a decade of acquisition experience grew its existing offices by 1.6%, which in most markets is below the rate at which fee schedules and payroll both moved. That is not a scandal. It is the normal condition of a business whose growth engine is purchasing, not operating. The roll-up thesis has always been that scale produces negotiating power with payers, cheaper supplies, centralized scheduling, and higher case acceptance. Those gains show up in the same-practice line or they do not exist. On this filing, in one of the two years, they essentially did not exist.

Now consider what that means for the equity you are being asked to hold. Rollover equity is not a share of your practice anymore. It is a share of a debt-loaded holding company whose operating performance looks like the above and whose exit depends on the next buyer paying more per dollar of EBITDA than the current one did.

More Than 100 Platforms, and They Are Buying Each Other

The reason DSOs now buy DSOs is arithmetic. There are more than 100 private-equity-backed DSOs today, and probably closer to 200, with the largest platform managing over 1,650 practices, according to McGuireWoods. Sponsors typically hold three to seven years before a secondary sale or recapitalization to another private-equity-backed platform. When a mid-size platform needs to show its investors an exit and the pool of individual practices worth buying has been picked over, the cleanest path is to sell the whole thing to a larger platform or a new sponsor.

McGuireWoods is also direct about what happens to you in that transaction: dentists who roll equity into the new platform often face a second, smaller liquidity event. Smaller. Not larger. The second bite gets described in LOI meetings as the part where the real money is made, and the firm's own counsel describes it as the part where you get less.

The consolidation itself is not speculative. Private-equity affiliation among dentists nearly doubled from 6.6% in 2015 to 12.8% in 2021, and PE-backed dental acquisitions went from fewer than 20 a year between 2004 and 2015 to 62 in 2019, 46 in 2020 and 96 in 2021, per ADA News reporting on peer-reviewed HPI research. DSO affiliation across all dentists more than doubled from 7.2% in 2015 to 16.1% in 2024, while the overall practice-ownership rate fell from 84.7% in 2005 to 72.5% in 2023, per the ADA Health Policy Institute's 2025 workforce report. The buyers are consolidating faster than the sellers are.

What Most Owners Get Wrong About the Rollover Line

The mistake is specific and it is made by a specific person: the owner between 52 and 62, doing $1.2 million to $2.5 million in collections, working with a broker whose fee is calculated on headline enterprise value, who compares two offers by their multiple and treats the rollover at face value.

They will say, out loud, something like "Offer A is 6.0 times with 30% rollover, Offer B is 5.25 times all cash, so A is better." That sentence adds a cash number to a non-cash number as if they were the same currency. They are not. The cash is yours on Friday. The rollover is an illiquid minority interest in a levered company, junior to debt, frequently junior to a sponsor's preferred return, subject to dilution every time the platform issues equity to buy the next practice, subject to a management incentive plan that takes its cut before common holders see anything, and governed by a shareholder agreement that gives you no ability to force a sale or block one.

The second mistake follows from the first. Owners negotiate hard on the multiple and sign the equity documents without a lawyer who reads debt-financed acquisition paper. The multiple is one number. The waterfall, the drag-along, the tag-along, the anti-dilution terms and the definition of a liquidity event are the actual deal.

Running $810,000 of Rollover Through a Secondary Sale

Take an owner with $450,000 of adjusted EBITDA after a market-rate dentist salary. At 6.0 times, enterprise value is $2.7 million. With 70% cash at close, they wire $1.89 million. The rollover is $810,000.

Assume the platform they join has $40 million of EBITDA, was bought at 10 times for $400 million enterprise value, carries $240 million of debt at six turns, and has $160 million of equity underneath it.

Downside case, and this is the one nobody models. The platform grows EBITDA at 1.6% a year, Park's 2024 same-practice rate, reaching $43.3 million in five years. Credit conditions tighten and the exit multiple compresses to 9 times, for $389.7 million of enterprise value. Debt is unchanged because free cash went into acquisitions, leaving $149.7 million of equity against $160 million at entry. That is 93.6% of entry value. Apply 25% dilution from equity issued for acquisitions and a 10% management incentive plan, and the owner's claim is worth 63.2% of what they rolled. The $810,000 returns about $512,000, five years later, before tax.

Upside case. EBITDA compounds at 8% to $58.8 million, the secondary clears at 12 times for $705.3 million, and equity is $465.3 million. That is 2.91 times entry equity. After the same dilution and incentive haircuts, the $810,000 becomes about $1.59 million. Then the new platform requires a 50% roll, so $795,000 comes in cash and $795,000 becomes a third illiquid chip.

Now price the alternative. The all-cash offer at 5.25 times is $2.3625 million, which is $472,500 more cash at close than the 70% structure. Put that in a taxable account at 7% for five years and it is roughly $663,000.

So: certain $663,000, versus $512,000 in the bad case and $795,000 of cash plus a new illiquid chip in the good case. The upside scenario, in which the platform grows EBITDA at 8% a year and exits at a two-turn premium, beats a plain brokerage account by about $132,000 over five years. That is the reward for taking minority equity risk in a debt-loaded company with no control and no exit. We wouldn't take that deal.

Your Buyer Will Not Be Your Buyer in Year Three

There is a non-financial cost that owners discover around month 20. Under a three-to-seven-year hold, the regional director who recruited you, promised you supply autonomy and said nothing would change clinically is an employee of a company that is about to be sold. None of their assurances survive the transaction. Your employment agreement does. Your non-compete does. Your production targets do. The verbal commitments go out with the old org chart.

If you are selling at 58 with an intention to work four more years, you should assume you will work for two or three different owners in that window, each with a new EBITDA target set by a sponsor who needs to show improvement before their own exit. Price that into the deal, or get your clinical autonomy terms into the actual contract with a cure period and a termination right attached.

Three Things to Do Before You Sign the LOI

Ask every bidder for a 100% cash price alongside their structured price, in writing, and compare only the cash columns. Have a corporate attorney who does debt-financed buyouts, not a dental transactions generalist, read the shareholder agreement and tell you in one page where your equity sits in the waterfall, what dilutes it, and what triggers a payout. Then ask the sponsor directly for same-practice revenue growth for the last two years across the whole platform, and treat a refusal as the answer. If the number is under 3%, you are being paid in paper issued by a company that cannot grow the offices it already owns.

What we are watching next: whether secondary sale multiples hold as debt costs stay elevated, because the entire second-bite promise depends on the next sponsor paying more per dollar of EBITDA than the current one did. If two or three mid-size platforms trade down this year, rollover terms across the market get worse fast. What would change our view is a platform publishing same-practice growth above 6% for three consecutive years. That would mean the operating thesis is real, and the equity would be worth something closer to what the pitch deck says.

Before you take any offer to the table, work out what your practice is worth on its own cash flow, independent of whatever structure a buyer proposes. Our valuation calculator will give you an EBITDA-based range in a few minutes so you can see exactly how much of a bidder's headline multiple is cash and how much is a promise. Run your own numbers, then go read the equity documents.